Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Seagrindon Dec 18, 2019 8:03am
171 Views
Post# 30467278

Announcement between now and mid-late Jan IMO

Announcement between now and mid-late Jan IMOWhy? Waiting until closer to March 15 (when Talent payment is due), doesn't leave any time for finalizing the deal (which usually takes months). My understanding is that when the term sheet gets incorporated into a binding agreement, the company must disclose this to the shareholders (after both board of directors approve the agreement). Then the company needs to hold a special shareholder's meeting as indicated above, after which the deal usually closes relatively soon. World Class Extractions, for example, entered into an agreement on April 17, 2019 to merge/buyout Quadron. The special shareholder's meeting was held June 10th and the deal closed June 17th. Assuming a similar time-frame, we should see an announcement sometime between now and mid-late Jan IMO (very soon). However, I still think it could happen this week so they can deal with the debentures due on Friday. If they find other means for financing, then sometime in Jan is likely IMO.
Bullboard Posts